I don’t have an exact timeline, and can’t prove anything, but it seems that CV deaths began to rise at about the same time as the FDA and various state pharmacy boards began to prohibit the use of HCQ for the CV.
“””I dont have an exact timeline, and cant prove anything, but it seems that CV deaths began to rise at about the same time as the FDA and various state pharmacy boards began to prohibit the use of HCQ for the CV.”””
FDA revoked the EUA for HCQ on June 15th.
The doctors probably had word thru the grapevine that HCQ use was going to be revoked so they may have stopped prescribing it before June 15th.
And yes, covid cases, hospitalizations, and deaths started going up in mid june.
Also, I believe DR Simone Gold did her first interview re HCQ and covid on June 18th-—just three days after FDA revoked the EUA for HCQ.
President Trump expressed optimism based on studies in France and China, and the media freaked out. The president’s political opposition would go on to cling to any proof the drug would not work and suppress any information that it would. This politicization culminated in the horrific study published by Lancet that the publication quietly retracted.
However, the damage was already done. The World Health Organization suspended trials immediately after the study published in Lancet. Switzerland, which had been using the treatment, prohibited the use of the drug in COVID-19 shortly after that on May 27th. The retraction was so stealth that the ban was not lifted in Switzerland until June 11th.
This window allowed French researchers to analyze what happened in the entire population of COVID-19 patients during the ban. They used the case fatality rate (CFR) as the measure observed. The graph is stunning.
It also the only period where the Swiss CFR approached or exceeded that in France where there has been no use of hydroxychloroquine outside a few isolated trials.
The CFR returned to the highest level it had been since early in the pandemic at over 15%. Upon resumption of treatment with hydroxychloroquine, it returned to below 5%. A statistical analysis of the data:
A statistically significant difference